Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis, Genomica Merger Finally Gets Stock-Exchange Ratio

SAN FRANCISCO, Dec. 26 - The proposed Genomica-Exelixis merger finally got its stock-exchange ratio. The ratio for converting shares of Genomica stock into shares of Exelixis stock will be 0.28306, the companies said on Wednesday .


The initial offering period for the exchange will expire midnight Eastern Standard Time on Dec. 28.


Exelixis announced on Nov. 19 plans to acquire Genomica in a stock deal valued at $110 million, and Genomica's board of directors unanimously recommended that the firm's stockholders accept the offer, according to the company.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.